Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
Abstract Objectives To determine (i) correlates for etanercept (ETA) discontinuation after achieving an inactive disease and for the subsequent risk of flare and (ii) to analyze the effectiveness of ETA in the re-treatment after a disease flare. Methods Data from two ongoing prospective registries,...
Main Authors: | Jens Klotsche, Ariane Klein, Martina Niewerth, Paula Hoff, Daniel Windschall, Ivan Foeldvari, Johannes-Peter Haas, Gerd Horneff, Kirsten Minden |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13075-021-02492-0 |
Similar Items
-
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
by: Gerd Horneff, et al.
Published: (2017-11-01) -
EFFICACY AND SAFETY OF ETANERCEPT TREATMENT IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS. THE RESULTS OF AN OPEN PROSPECTIVE STUDY ON THE BASIS OF THE SCIENTIFIC CENTER OF CHILDREN'S HEALTH (MOSCOW)
by: Ekaterina I. Alekseeva, et al.
Published: (2016-11-01) -
Etanercept In the treatment of AA-amyloidosis in juvenile rheumatoid arthritis
by: H Mihels
Published: (2004-08-01) -
Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry
by: Giulia Armaroli, et al.
Published: (2020-10-01) -
EFFICACY OF ETANERCEPT IN TREATMENT OF VARIOUS TYPES OF JUVENILE IDIOPATHIC ARTHRITIS
by: O. Yu. Konopel'ko, et al.
Published: (2013-12-01)